Welcome to the international HTA database

Showing [24014 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2024	NIHR Health Technology Assessment programme	Software with artificial intelligence-derived algorithms for analysing CT brain scans in people with a suspected acute stroke: a systematic review and cost-effectiveness analysis
2024	National Institute for Health and Care Excellence (NICE)	Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema. NICE technology appraisal guidance 953
2024	NIHR Health Technology Assessment programme	Specific phobias in children with moderate to severe intellectual disabilities: SPIRIT, an adaptation and feasibility study
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: prolotherapy's efficacy and safety in the treatment of chronic musculoskeletal pain]
2024	Institute for Clinical and Economic Review (ICER)	Tabelecleucel for epstein-barr virus positive post-transplant lymphoproliferative disease: effectiveness and value
2024	NIHR Health Technology Assessment programme	A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic Chronic Subdural Haematoma (Dex-CSDH trial)
2024	National Institute for Health and Care Excellence (NICE)	Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations. NICE technology appraisal guidance 952
2024	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Avapritinib (new therapeutic indication: indolent systemic mastocytosis (ISM))]
2024	Institute for Clinical and Economic Review (ICER)	Managing the challenges of paying for gene therapy: strategies for market action and policy reform
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Safety and effectiveness of non-invasive management of pectus excavatum with vacuum bell therapy]
2024	NIHR Health Technology Assessment programme	Lower urinary tract symptoms in men: the TRIUMPH cluster RCT
2024	National Institute for Health and Care Excellence (NICE)	Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer. NICE technology appraisal guidance 951
2024	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Momelotinib (myelofibrosis)]
2024	Institute for Clinical and Economic Review (ICER)	Unsupported price increase report: unsupported price increases occurring in 2023
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Exposure therapy with virtual reality in adults with specific phobia]
2024	NIHR Health Technology Assessment programme	Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT
2024	National Institute for Health and Care Excellence (NICE)	Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over. NICE technology appraisal guidance 950
2024	Norwegian Medical Products Agency (NOMA)	[Interferon gamma-1b for treatment of Friedreich’s ataxia: a health technology assessment without submitted documentation]
2024	Institute for Clinical and Economic Review (ICER)	Assessment of barriers to fair access
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula. Update]
2024	NIHR Health Technology Assessment programme	Surgical versus non-surgical management of lateral compression type-1 pelvic fracture in adults 60 years and older: the L1FE RCT
2024	National Institute for Health and Care Excellence (NICE)	Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over. NICE technology appraisal guidance 949
2024	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Effectiveness and safety of deep brain stimulation in severe and treatment-resistant obsessive-compulsive disorder]
2024	National Institute for Health and Care Excellence (NICE)	Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments. NICE technology appraisal guidance 948
2024	National Institute for Health and Care Excellence (NICE)	Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 947
2024	Institute for Clinical Effectiveness and Health Policy (IECS)	[Percutaneous treatment for moderate to severe mitral valve insufficiency]
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: urethral discharge - diagnostic measures and pharmacological treatment]
2024	National Institute for Health and Care Excellence (NICE)	Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. NICE technology appraisal guidance 946
2024	National Institute for Health and Care Excellence (NICE)	Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal). NICE technology appraisal guidance 945
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: hormone therapy for the management of the clinical manifestations of menopause]
2024	Canadian Agency for Drugs and Technologies in Health (CADTH)	Ketamine for adults with treatment-resistant depression or posttraumatic stress disorder: a 2023 update
2024	National Institute for Health and Care Excellence (NICE)	Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer. NICE technology appraisal guidance 944
2024	Penn Medicine Center for Evidence-based Practice (CEP)	Public health preparedness for mass gatherings
2024	NIHR Health Technology Assessment programme	Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis
2024	Canadian Agency for Drugs and Technologies in Health (CADTH)	Ketamine for adults with substance use disorders
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: COVID-19 - optimal use of parmacological treatments]
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[Newsletter: access to innovations in health and social services - financing and decision-making]
2024	Scottish Health Technologies Group (SHTG)	Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2024	Canadian Agency for Drugs and Technologies in Health (CADTH)	Ketorolac for renal colic
2024	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: overview – comparison, based on health profile, of the use of primary care medical services by persons registered with a family physician and those who are not]
2024	Swiss Federal Office of Public Health (FOPH)	Trikafta® for the treatment of patients with cystic fibrosis: an exploratory economic evaluation
2024	Canadian Agency for Drugs and Technologies in Health (CADTH)	Clinical and instrumental swallowing assessments for dysphagia
2024	Institute for Clinical Effectiveness and Health Policy (IECS)	[Magnetic resonance neurography in peripheral neuropathy or plexopathy]
2024	Center for Drug Evaluation (CDE)	[Health Technology Assessment Report : Opdivo (gastric cancer - GC)]
2024	Scottish Health Technologies Group (SHTG)	Volatile capture technologies
2024	Canadian Agency for Drugs and Technologies in Health (CADTH)	Timing of antibiotic therapy for neisseria gonorrhoeae infection
2024	NIHR Health Technology Assessment programme	Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT
2024	Scottish Health Technologies Group (SHTG)	Digital cancer prehabilitation
2024	Canadian Agency for Drugs and Technologies in Health (CADTH)	Intra-articular hyaluronic acid for osteoarthritis of the hip, shoulder, and ankle
2024	NIHR Health Technology Assessment programme	Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT
2024	Scottish Health Technologies Group (SHTG)	Clopidogrel genotype testing after ischaemic stroke or transient ischaemic attack (TIA) - SHTG Assessment
2024	Canadian Agency for Drugs and Technologies in Health (CADTH)	Aerosol therapy with inhalers during mechanical ventilation
2024	National Institute for Health and Care Excellence (NICE)	Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension. NICE technology appraisal guidance 1009
2024	Canadian Agency for Drugs and Technologies in Health (CADTH)	Opioid-sparing effects of IV acetaminophen for patients undergoing surgery
2024	National Institute for Health and Care Excellence (NICE)	Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments. NICE technology appraisal guidance 1008
2024	Penn Medicine Center for Evidence-based Practice (CEP)	Indications for urinary catheterization in sedated patients
2024	NIHR Health Technology Assessment programme	Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)
2024	HTA South	[Artificial intelligence in breast cancer screening with mammography]
2024	National Institute for Health and Care Excellence (NICE)	Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. NICE technology appraisal guidance 1007
2024	Institute for Clinical Effectiveness and Health Policy (IECS)	[Partially hydrolyzed formula to prevent cow’s milk allergy]
2024	Center for Drug Evaluation (CDE)	[HTA for Medical Device: Metallic biliary stents (Rapid HTA report)]
2023	WorkSafeBC	Cold plunges as treatment for concussions
2023	WorkSafeBC	The effect of pepper spray on human health
2023	HTA South	[Focused ultrasound treatment for tremor]
2023	WorkSafeBC	Koebner phenomenon in connective tissue
2023	Adelaide Health Technology Assessment (AHTA)	Newborn bloodspot screening for sickle cell disease
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: Optune - for the treatment of adult patients with newly diagnosed glioblastoma]
2023	WorkSafeBC	Glutamine for treating concussions
2023	Adelaide Health Technology Assessment (AHTA)	Newborn bloodspot screening for sickle cell disease and beta thalassaemia
2023	WorkSafeBC	Creatine supplementation for treating concussions
2023	NIHR Health Services and Delivery Research programme	Impact of interventions to improve recovery of older adults following planned hospital admission on quality-of-life following discharge: linked-evidence synthesis
2023	NIHR Health Services and Delivery Research programme	The effectiveness and acceptability of multimedia information when recruiting children and young people to trials: the TRECA meta-analysis of SWATs
2023	NIHR Health Technology Assessment programme	The potential impact of policies and structural interventions in reducing cardiovascular disease and mortality: a systematic review of simulation-based studies
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Dental bridges for partial tooth loss
2023	NIHR Health Services and Delivery Research programme	Evaluating mental health decision units in acute care pathways (DECISION): a quasi-experimental, qualitative and health economic evaluation
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Mortality review 2023 update
2023	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Evondos® medicine-dispensing service
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatment of adult patients with chronic immune thrombocytopenia after failure of first-line therapies
2023	NIHR Health Technology Assessment programme	Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis
2023	Ontario Health	Bariatric surgery for people with class I obesity and poorly controlled type 2 diabetes
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Rapid response: Cervical cancer: transition from from Pap test screening to HPV testing]
2023	NIHR Health Technology Assessment programme	Treatment of Hidradenitis Suppurativa Evaluation Study: the THESEUS prospective cohort study
2023	Ontario Health	Testing for homologous recombination deficiency in patients diagnosed with ovarian cancer
2023	Institute for Clinical and Economic Review (ICER)	Fezolinetant for moderate to severe vasomotor symptoms associated with menopause: effectiveness and value
2023	NIHR Health Technology Assessment programme	Techniques to increase lumbar puncture success in newborn babies: the NeoCLEAR RCT
2023	Ontario Health	Wire-free, nonradioactive localization techniques to guide surgical excision of nonpalpable breast cancer tumours
2023	Ontario Health	Placental growth factor (PlGF)-based biomarkers for risk prediction in people with suspected preeclampsia
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Image-guided spinal injections in the treatment of chronic spinal pain: an overview of evidence-based guideline recommendations and specific focus on guidance techniques
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Robot-assisted rehabilitation for incomplete spinal cord injury]
2023	Institute for Clinical and Economic Review (ICER)	Gene therapies for sickle cell disease: effectiveness and value
2023	Austrian Institute for Health Technology Assessment (AIHTA)	SMA therapies: mid- to long-term follow-up of spinal muscular atrophy (SMA) patients treated for ≥24 months with nusinersen or onasemnogene abeparvovec and ≥12 months for patients treated with risdiplam or combination therapies
2023	Institute for Clinical and Economic Review (ICER)	Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH)
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Strategies for recruitment and programme adherence in group programmes for children, adolescents and adults with overweight and grade 1 obesity]
2023	Institute for Clinical and Economic Review (ICER)	Lecanemab for early Alzheimer’s disease
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Myopia control spectacle lenses for children and adolescents]
2023	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effectiveness evaluation of andexanet alfa (Ondexxya)]
2023	Institute for Clinical and Economic Review (ICER)	Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Registries in Austria and their utilisation for healthcare improvement]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Autologous fat grafting in osteoarthritis]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Endovenous laser therapy for varicose veins in the lower extremities]